-
甲状腺癌是内分泌系统最常见的一种恶性肿瘤,约占全身恶性肿瘤的1%,近年来其发病率迅速上升[1]。在所有甲状腺癌中,DTC的占比最高,可达90%,其治疗方法多以外科手术为主,辅以甲状腺激素抑制治疗和131I治疗,某些情况下还可行局部放疗或靶向治疗。经过治疗后大多数DTC患者预后良好,但仍有部分患者会出现复发和转移,其中约1/3的患者病灶摄取碘的能力逐渐降低甚至丧失[2],导致131I全身显像对其的诊断灵敏度降低,出现显像结果阴性的情况,这使得此类患者的常规后续管理面临严峻挑战。近年来PET/CT在临床中不断普及,其在DTC复发和转移患者的诊断和治疗中具有很好的临床实用价值,笔者对其综述如下。
PET/CT在分化型甲状腺癌复发和转移诊断中的应用进展
Application progress of PET/CT in the diagnosis of recurrences and metastases of differentiated thyroid cancer
-
摘要: 分化型甲状腺癌(DTC)的发病率呈逐年上升趋势,大部分患者预后良好,但当DTC发生复发和转移时,患者生存率明显下降,因此,对DTC患者复发和转移的诊断、评估以及治疗显得尤为重要。随着PET/CT在肿瘤学领域研究的不断开展,其在DTC复发和转移患者中的应用越来越受到重视,可为其精准诊疗提供重要信息。笔者就PET/CT在DTC复发和转移诊断中的应用进展进行综述。
-
关键词:
- 肿瘤转移 /
- 分化型甲状腺癌 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 肿瘤复发
Abstract: The incidence of differentiated thyroid cancer (DTC) is increasing annually, and most patients have excellent prognoses. However, the survival rate decreases significantly in patients with recurrences and metastases. Therefore, the detection, evaluation, and treatment for the recurrences and metastases of DTC are particularly crucial. With the continuous progress of PET/CT research in oncology, its application value has received increasing attention in such patients; it also provides important information for accurate diagnoses and treatment methods. In this study, the authors review the application progress of PET/CT in the diagnosis of recurrences and metastases of DTC. -
[1] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [2] Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 356−358. DOI: 10.1016/S2213-8587(13)70215-8. [3] 吴亚, 曹星月, 邓红艳, 等. 细针穿刺标本中葡萄糖转运体1基因检测在诊断甲状腺癌中的价值[J]. 南京医科大学学报: 自然科学版, 2018, 38(8): 1107−1112. DOI: 10.7655/NYDXBNS20180818.
Wu Y, Cao XY, Deng HY, et al. Glucose transporter 1 gene of fine needle aspiration specimen in the diagnosis of thyroid cancer[J]. J Nanjing Med Univ (Nat Sci), 2018, 38(8): 1107−1112. DOI: 10.7655/NYDXBNS20180818.[4] Boktor RR, Lee ST, Berlangieri SU, et al. Impact of 18F-FDG PET/CT on treatment of patients with differentiated thyroid carcinoma, negative 131I whole body scan and elevated serum thyroglobulin[J]. Asia Ocean J Nucl Med Biol, 2022, 10(1): 20−27. DOI: 10.22038/AOJNMB.2021.58276.1406. [5] Albano D, Tulchinsky M, Dondi F, et al. The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan[J]. Endocrine, 2021, 74(2): 332−339. DOI: 10.1007/s12020-021-02755-5. [6] Liu J, Liu BP, Yu YX, et al. 18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan[J]. Hell J Nucl Med, 2018, 21(1): 24−27. DOI: 10.1967/s002449910703. [7] Leboulleux S, El Bez I, Borget I, et al. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels[J]. Thyroid, 2012, 22(8): 832−838. DOI: 10.1089/thy.2012.0081. [8] Rizzini EL, Repaci A, Tabacchi E, et al. Impact of 18F-FDG PET/CT on clinical management of suspected radio-iodine refractory differentiated thyroid cancer (RAI-R-DTC)[J/OL]. Diagnostics, 2021, 11(8): 1430[2022-06-08]. https://www.mdpi.com/2075-4418/11/8/1430. DOI: 10.3390/diagnostics11081430. [9] Weber M, Binse I, Nagarajah J, et al. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer[J]. Q J Nucl Med Mol Imaging, 2019, 63(3): 235−252. DOI: 10.23736/S1824-4785.19.03201-1. [10] Wierts R, Brans B, Havekes B, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT[J]. J Nucl Med, 2016, 57(7): 1027−1032. DOI: 10.2967/jnumed.115.168799. [11] Plyku D, Hobbs RF, Wu D, et al. I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response[J]. Ann Nucl Med, 2022, 36(3): 213−223. DOI: 10.1007/s12149-021-01655-y. [12] Santhanam P, Taieb D, Solnes L, et al. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis[J]. Clin Endocrinol, 2017, 86(5): 645−651. DOI: 10.1111/cen.13306. [13] Wu D, Ylli D, Heimlich SL, et al. 124I positron emission tomography/computed tomography versus conventional radioiodine imaging in differentiated thyroid cancer: a review[J]. Thyroid, 2019, 29(11): 1523−1535. DOI: 10.1089/thy.2018.0598. [14] Wu D, Plyku D, Kulkarni K, et al. Optimal time for 124I PET/CT imaging in metastatic differentiated thyroid cancer[J]. Clin Nucl Med, 2021, 46(4): 283−288. DOI: 10.1097/RLU.0000000000003505. [15] Niu MD, Qin JJ, Wang L, et al. Evaluation of [18F]tetrafluoroborate as a potential PET imaging agent in a sodium iodide symporter-transfected cell line A549 and endogenous NIS-expressing cell lines MKN45 and K1[J]. Mol Imaging, 2022, 2022: 2679260. DOI: 10.1155/2022/2679260. [16] O'Doherty J, Jauregui-Osoro M, Brothwood T, et al. 18F-tetrafluoroborate, a PET probe for imaging sodium/iodide symporter expression: whole-body biodistribution, safety, and radiation dosimetry in thyroid cancer patients[J]. J Nucl Med, 2017, 58(10): 1666−1671. DOI: 10.2967/jnumed.117.192252. [17] Jiang HL, Schmit NR, Koenen AR, et al. Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects[J/OL]. EJNMMI Res, 2017, 7(1): 90[2022-06-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-017-0337-5. DOI: 10.1186/s13550-017-0337-5. [18] Samnick S, Al-Momani E, Schmid JS, et al. Initial clinical investigation of [18F]tetrafluoroborate PET/CT in comparison to [124I]iodine PET/CT for imaging thyroid cancer[J]. Clin Nucl Med, 2018, 43(3): 162−167. DOI: 10.1097/RLU.0000000000001977. [19] Dittmann M, Carvalho JMG, Rahbar K, et al. Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(11): 2639−2646. DOI: 10.1007/s00259-020-04727-9. [20] Moore M, Panjwani S, Mathew R, et al. Well-differentiated thyroid cancer neovasculature expresses prostate-specific membrane antigen—a possible novel therapeutic target[J]. Endocr Pathol, 2017, 28(4): 339−344. DOI: 10.1007/s12022-017-9500-9. [21] Heitkötter B, Steinestel K, Trautmann M, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid[J/OL]. Oncotarget, 2018, 9(11): 9867−9874[2022-06-08]. https://www.oncotarget.com/article/23984/text. DOI: 10.18632/oncotarget.23984. [22] Sollini M, Di Tommaso L, Kirienko M, et al. PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome[J/OL]. EJNMMI Res, 2019, 9(1): 93[2022-06-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-019-0559-9. DOI: 10.1186/s13550-019-0559-9. [23] Santhanam P, Russell J, Rooper LM, et al. The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer[J]. Med Oncol, 2020, 37(11): 98. DOI: 10.1007/s12032-020-01427-0. [24] Pitalua-Cortes Q, García-Perez FO, Vargas-Ahumada J, et al. Head-to-head comparison of 68Ga-PSMA-11 and 131I in the follow-up of well-differentiated metastatic thyroid cancer: a new potential theragnostic agent[J/OL]. Front Endocrinol, 2021, 12: 794759[2022-06-08]. https://www.frontiersin.org/articles/10.3389/fendo.2021.794759/full. DOI: 10.3389/fendo.2021.794759. [25] Verma P, Malhotra G, Meshram V, et al. Prostate-specific membrane antigen expression in patients with differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy using 68Ga-PSMA-HBED-CC PET/CT[J]. Clin Nucl Med, 2021, 46(8): e406−e409. DOI: 10.1097/RLU.0000000000003655. [26] Lawhn-Heath C, Yom SS, Liu C, et al. Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study[J/OL]. EJNMMI Res, 2020, 10(1): 128[2022-06-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-00720-3. DOI: 10.1186/s13550-020-00720-3. [27] de Vries LH, Lodewijk L, Braat AJAT, et al. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617[J/OL]. EJNMMI Res, 2020, 10(1): 18[2022-06-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0610-x. DOI: 10.1186/s13550-020-0610-x. [28] 中华医学会核医学分会, 中国生物物理学会分子影像学分会. 整合素RGD受体显像临床应用专家共识(2022版)[J]. 协和医学杂志, 2022, 13(2): 227−234. DOI: 10.12290/xhyxzz.2022-0089.
Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert consensus on clinical application of integrin RGD receptor imaging (2022)[J]. Med J Peking Union Med Coll Hosp, 2022, 13(2): 227−234. DOI: 10.12290/xhyxzz.2022-0089.[29] Klubo-Gwiezdzinska J, Chen XY. Targeting integrins with radiolabeled RGD analogues for radiotheranostics of metastatic radioactive iodine nonresponsive thyroid cancer: new avenues in personalized medicine[J]. Thyroid, 2020, 30(4): 476−478. DOI: 10.1089/thy.2020.0169. [30] Parihar AS, Mittal BR, Kumar R, et al. 68Ga-DOTA-RGD2 positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics[J]. Thyroid, 2020, 30(4): 557−567. DOI: 10.1089/thy.2019.0450. [31] Parihar AS, Sood A, Kumar R, et al. Novel use of 177Lu-DOTA-RGD2 in treatment of 68Ga-DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS[J]. Eur J Nucl Med Mol Imaging, 2018, 45(10): 1836−1837. DOI: 10.1007/s00259-018-4036-x. [32] Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415−1422. DOI: 10.2967/jnumed.118.210443. [33] Hathi DK, Jones EF. 68Ga FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J/OL]. Radiol Imaging Cancer, 2019, 1(1): e194003[2022-06-08]. https://pubs.rsna.org/doi/10.1148/rycan.2019194003. DOI: 10.1148/rycan.2019194003. [34] Chen HJ, Pang YZ, Wu JX, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1820−1832. DOI: 10.1007/s00259-020-04769-z. [35] Cho JG, Byeon HK, Oh KH, et al. Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis[J]. Eur Arch Otorhinolaryngol, 2018, 275(9): 2355−2361. DOI: 10.1007/s00405-018-5061-x. [36] Fu H, Fu J, Huang JX, et al. 68Ga-FAPI PET/CT in thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy[J]. Clin Nucl Med, 2021, 46(5): 427−430. DOI: 10.1097/RLU.0000000000003569. [37] Fu H, Fu J, Huang JX, et al. 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for detecting metastatic lesions in a case of radioiodine-refractory differentiated thyroid cancer[J]. Clin Nucl Med, 2021, 46(11): 940−942. DOI: 10.1097/RLU.0000000000003730. [38] Watabe T, Liu YW, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl Med, 2020, 61(4): 563−569. DOI: 10.2967/jnumed.119.233122. [39] Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin Invest, 2006, 116(7): 1955−1962. DOI: 10.1172/jci26532. [40] Ballal S, Yadav MP, Moon ES, et al. Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study[J]. Thyroid, 2022, 32(1): 65−77. DOI: 10.1089/thy.2021.0412.
计量
- 文章访问数: 3519
- HTML全文浏览量: 2966
- PDF下载量: 20